The design of new cholinesterase inhibitors is based on modifying the structure of existing carbamate cholinesterase inhibitors or synthesizing carbamate derivatives of existing AD drugs to find new, more effective drugs for the treatment of neurodegenerative diseases. This evidence concerns the gene BCHE and Alzheimer disease.